Skip to main content
OpenTrials
Completed

NCT Number: NCT01987284

SER100 in Isolated Systolic Hypertension

Isolated Systolic Hypertension (ISH)is the dominating hypertensive disease in elderly people. Much attention has recently been drawn to the strong relationship between the systolic blood pressure and cardiovascular morbidity.

In previous clinical studies carried out in individuals with normal blood pressure at baseline SER100 decreased primarily the systolic blood pressure. It is hypothesized that the effect on systolic blood pressure in hypertensive patients will be larger or equal to the fall seen in normotensive patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

FinnMedi Oy/Valkeakoski District Hospital, Tampere, Finland

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Mean systolic blood pressure ≥ 150 mmHg and mean diastolic blood pressure < 90 mmHg - as determined by daytime continuous ambulatory blood pressure measurement (ABPM)
  • Male or female
  • Age 50-80 years (both inclusive) at screening
  • Patients must be on stable doses with one or more antihypertensives
  • BMI <32 kg/m2
  • Written informed consent

Exclusion criteria

  • Acute myocardial infarction in the last 6 months before screening
  • Stroke in the last 6 months before screening
  • Uncompensated heart failure (NYHA Class IV)
  • Angina pectoris with an anticipated need for administration of short-acting nitrates
  • Known, severe sleep apnoea
  • Abnormal laboratory values (i.e. > 2 x upper normal limit) at screening
  • Subjects working night shifts (11 PM to 7 AM)
  • Participation in any other clinical trial with an investigational medicinal product or device within 1 month prior to randomisation.
  • Subjects with upper arm circumference ≤24 cm or ≥ 42 cm.
  • Any general condition, serious disease or current evidence of any mental or physical disorder or collaboration attitude (e.g. dementia, substance abuse) which, in the judgment of the investigator makes the subject unsuitable for enrollment, and/or may interfere with the study evaluations or affect subject's safety and/or may cause risk for poor protocol compliance
  • Pregnant or lactating women.
  • Female subjects of childbearing potential, or male subjects whose female partner (unless post-menopausal for 1 year or surgically sterile) is unwilling to use adequate contraceptive measures throughout the duration of the study

Treatment and study plan

SER100

Drug

Placebo

Drug

Primary outcomes

  1. Number of participants with adverse events

    Time frame: Up to 4 weeks

Secondary outcomes

  1. Change from baseline in systolic blood pressure

    Time frame: Up to 4 weeks

Sponsors and collaborators

Lead sponsor

Serodus AS

Industry

Collaborators

  • Smerud Medical Research International AS
  • The Research Council of Norway

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Nov 19, 2013
Registry last updated
Oct 20, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.